Ipsen: Dysport promotion agreement in the US.
(CercleFinance.com) - Ipsen has announced a three-year exclusive agreement with Saol Therapeutics for the promotion of Dysport Injection in US-approved therapeutic indications in adults and lower-limb spasticity in children.
Under the terms of the agreement, Saol Therapeutics' sales force will promote Dysport to healthcare professionals, extended to hospitals from August 2017.
The French laboratory will maintain the current number of sales representatives entirely dedicated to Dysport in all its therapeutic indications. Other details of the agreement have not been disclosed.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Under the terms of the agreement, Saol Therapeutics' sales force will promote Dysport to healthcare professionals, extended to hospitals from August 2017.
The French laboratory will maintain the current number of sales representatives entirely dedicated to Dysport in all its therapeutic indications. Other details of the agreement have not been disclosed.
Copyright (c) 2017 CercleFinance.com. All rights reserved.